PUBLICATIONS

The following is a list of Prof. Anthony Dixon's publications in peer reviewed journals:

 1.      January 2026    Nirenberg, A., Williams, R., Steinman, H. Anderson, S. and Dixon, A. J., "The Melanoma Pathology Report: What to Expect and How to Interpret It." J Dermatol 53(1): 3–13.

Pathological information is critical to patient management in melanoma. A uniform approach based on current evidence is crucial and is summarized in this paper. Essential clinical and pathological parameters to report are the BAUSSS biomarker prognostic criteria, that is, Breslow thickness, patient age, presence of ulceration, melanoma subtype, patient sex, and anatomic site. Other important parameters to include are adnexal and periadnexal extension, tumor infiltrating lymphocytes, intravascular and abluminal lymphovascular invasion, microsatellites, in-transit metastases, perineural invasion, and margins. Additional parameters that have been recommended for inclusion are mitotic activity, regression, association with nevi and atypical melanocytic hyperplasia. The significance of special stains and genetic studies is also discussed.

2.      June 2025          Kyrgidis, A., Dixon, A. J., Sladden, M., Steinman, H. K., Zouboulis, C. C., Lallas, A., Schneider, S., Smith, H., Nirenberg, A., Longo, C., Argenziano, G., Popescu, C., Tzellos, T., Anderson, S. and Thomas, J. M. et al.  "Sentinel lymph node biopsy may no longer be a critical and component of melanoma management." J Eur Acad Dermatol Venereol 39(6): e550–e551.

3.      May 2025           Steinman, H. K. and A. J. Dixon. "Squamous Cell Carcinoma In Situ on High-Risk Sites and With Larger Sizes Require More Stages for Clearance With Mohs Surgery." J Drugs Dermatol 24(5): 494–497.

BACKGROUND: Few studies have evaluated Mohs micrographic surgery (MMS) for the treatment of squamous cell carcinoma in situ or evaluated the results by Mohs Appropriate Use Criteria. OBJECTIVE: Evaluate the clinical and surgical characteristics of squamous cell carcinoma in situ treated with MMS and categorize the results by Mohs Appropriate Use Criteria. METHODS AND MATERIALS: A single Mohs surgeon, prospective, longitudinal cohort study of all squamous cell carcinoma in situ tumors treated with MMS between April 2018 and May 2021. RESULTS: A total of 485 tumors were treated and 96.9% were primary tumors. Mean age of patients was 73.8 years; 80.6% were male. Mean tumor length, wound length, and subclinical extension were 0.98 cm, 1.58 cm, and 0.7 cm, respectively. These dimensions were lowest in Area H and highest in Area L. Mean stages to clear margins was 1.14. Area H tumors required significantly more stages than those in Areas M and L (P=0.031). CONCLUSIONS: Mean tumor and wound sizes, stages to clearance, and subclinical extension were lower than previously reported. Area H tumors required more stages to clearance than those in Areas M and L. Stages to clearance increased with increased tumor size. Curettage before surgery did not decrease the number of required stages to achieve clear tumor margins. CITATION: Steinman HK, Dixon AJ. Squamous cell carcinoma in situ on high-risk sites and with larger sizes require more stages for clearance with Mohs surgery.

4.      April 2025          Dixon, A. J., et al. "BAUSSS biomarker improves melanoma survival risk assessment." J Eur Acad Dermatol Venereol 39(4): 865–870.

BACKGROUND: The American Joint Committee on Cancer (AJCC) method of staging melanoma is dated and inaccurate. It ignores important prognostic melanoma features, especially the patient's age. BAUSSS is more accurate in determining survival risk for primary cutaneous melanoma patients who have no clinical or imaging evidence of nodal or distant metastases. BAUSSS is an algorithm incorporating analysis of Breslow thickness, Age, Ulceration, Subtype of melanoma, Sex and Site. These are the six features from the patient history along with the details from the melanoma pathology report that are most predictive of mortality outcome. OBJECTIVE: To develop a single-page document that allows the clinician to determine BAUSSS biomarker-predicted prognosis in consultation with the patient. METHOD: From various data sources, we developed an algorithm to predict melanoma mortality using the BAUSSS biomarker system. The single-page algorithm was made available to download at https://globalmelanoma.net/bausss-survival-chart, thus being readily available without charge to all clinicians and their patients. RESULTS: BAUSSS method of determining melanoma prognosis is more accurate and less costly than the AJCC staging system. The only surgery the patient requires is wide local excision of the primary tumour. This method of ascertaining melanoma risk does not require added surgery, costs, hospitalization, tests and anaesthesia, such as would be required if sentinel lymph node biopsy was undertaken. BAUSSS can be a useful tool in determining which primary melanoma patients are at sufficiently high risk to be considered for adjuvant drug therapy. CONCLUSIONS: We encourage clinicians to download and print in colour this single-page BAUSSS mortality prediction tool, laminate it, and use it face to face with the patient in consultations. Not only will the patient be able to recognize his/her long-term prognosis but will also be able to see how their tumour severity compares with others.

5.      January 2025    Dixon, A. J., et al. "Reply to Pennington, T.E.; Thompson, J.F. Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on "Dixon et al. Primary Cutaneous Melanoma-Management in 2024. J. Clin. Med. 2024, 13, 1607"." J Clin Med 14(1).

6.      September 2024 Dixon, A. J., et al. "BAUSSS biomarker further validated as a key risk staging tool for patients with primary melanoma." J Eur Acad Dermatol Venereol 38(9): e779–e781.

7.      August 2024     Zouboulis, C. C., Zouboulis, C. C., Dixon, A. J., Steinman, H. K., Sladden, M. and Kyrgidis, A.et al. "Age-associated metastatic potential of melanoma in lymph nodes: A preliminary gene association study." J Eur Acad Dermatol Venereol 38(8): e701–e707.

8.      June 2024          Dixon, A. J., et al. "Primary Cutaneous Melanoma-Management in 2024." J Clin Med 13(6).

Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly when considering patient age. Objective: to provide an update on melanoma management from the time of the decision to biopsy a suspicious skin lesion. Methods: We reviewed melanoma-management research published between 2018 and 2023 and identified where such findings impact and update the management of confirmed melanomas. Pubmed, Google Scholar, Ovid and Cochrane Library were used as search tools. Results: We identified 81 publications since 2017 that have changed melanoma management; 11 in 2018, 12 in 2019, 10 in 2020, 12 in 2021, 17 in 2022 and 18 in 2023. Discussion: Delayed or inaccurate diagnosis is more likely to occur when a partial shave or punch biopsy is used to obtain the histopathology. Wherever feasible, a local excision with a narrow margin should be the biopsy method of choice for a suspected melanoma. The Breslow thickness of the melanoma remains the single most important predictor of outcome, followed by patient age and then ulceration. The BAUSSS biomarker, (Breslow thickness, Age, Ulceration, Subtype, Sex and Site) provides a more accurate method of determining mortality risk than older currently employed approaches, including sentinel lymph node biopsy. Patients with metastatic melanomas and/or nodal disease should be considered for adjuvant drug therapy (ADT). Further, high-risk melanoma patients are increasingly considered for ADT, even without disease spread. Invasive melanomas less than 1 mm thick are usually managed with a radial excision margin of 10 mms of normal skin. If the thickness is 1 to 2 mm, select a radial margin of 10 to 20 mm. When the Breslow thickness is over 2 mm, a 20 mm clinical margin is usually undertaken. In situ melanomas are usually managed with a 5 to 10 mm margin or Mohs margin control surgery. Such wide excisions around a given melanoma is the only surgery that can be regarded as therapeutic and required. Patients who have had one melanoma are at increased risk of another melanoma. Ideal ongoing management includes regular lifelong skin checks. Total body photography should be considered if the patient has many naevi, especially when atypical/dysplastic naevi are identified. Targeted approaches to improve occupational or lifestyle exposure to ultraviolet light are important. Management also needs to include the consideration of vitamin D supplementary therapy.

9.      April 2024          Dixon, A. J., et al. "Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients." J Eur Acad Dermatol Venereol 38(4): 741–751.

BACKGROUND: Melanoma disease patterns vary with patient age. AIM: To evaluate sentinel lymph node biopsy (SLNB) in managing melanoma at differing patient ages. METHODS: Online prediction tools were applied to compare SLNB positivity (SLNB(+)) and survival risk at patient ages 20-80. Tubingen melanoma data were used to determine variations in the hazard ratio of SLNB(+) for mortality at different patient ages. RESULTS: Regardless of tumour thickness, predicted SLNB(+) rates were markedly higher than mortality rates for 20-year-old patients. For 80-year-old patients, it is the opposite. DISCUSSION: If 1000 20-year-olds with a 0.4 mm thickness non-ulcerated melanoma underwent SLNB, 100 would likely be positive. If all 100 were to be offered adjuvant drug therapy (ADT), fewer than three more melanoma deaths in those 1000 patients would be avoided. In total, 97 patients would have received medication they may never have needed. If 1000 80-year-olds with a 3 mm thickness non-ulcerated melanoma underwent SLNB, only 40 would likely be positive. In total, 274 patients would be predicted to die of melanoma, 245 being SLNB negative and 29 SLNB(+). ADT linked to SLNB(+) could deny treatment to 89% of these high-risk patients. LIMITATIONS: The authors relied on published risk data. CONCLUSION: SLNB has poor specificity at predicting mortality in young melanoma patients and poor sensitivity in older patients. SLNB is not indicated in managing cutaneous melanoma for patients under 40 or over 60 years of age. Many such patients could be managed with wide local excision alone in their clinician's office-based practice. For all cutaneous melanoma patients at all ages, linking ADT to BAUSSS biomarker, (an algorithm of Breslow thickness, age, ulceration, subtype, sex and Site) rather than SLNB(+) is likely more appropriate. BAUSSS provides a more accurate melanoma-specific mortality risk assessment for patients without burdening them with added surgery, hospitalization, costs or morbidity risk.

10.  October 2023                 Dixon, A.J., et al. "Online prediction tools for melanoma survival: A comparison." J Eur Acad Dermatol Venereol 37(10): 1999–2003.

BACKGROUND: Breslow thickness, patient age and ulceration are the three most valuable clinical and pathological predictors of melanoma survival. A readily available reliable online tool that accurately considers these and other predictors could be valuable for clinicians managing melanoma patients. OBJECTIVE: To compare online melanoma survival prediction tools that request user input on clinical and pathological features. METHODS: Search engines were used to identify available predictive nomograms. For each, clinical and pathological predictors were compared. RESULTS: Three tools were identified. The American Joint Committee on Cancer tool inappropriately rated thin tumours as higher risk than intermediate tumours. The University of Louisville tool was found to have six shortcomings: a requirement for sentinel node biopsy, unavailable input of thin melanoma or patients over 70 years of age and less reliable hazard ratio calculations for age, ulceration and tumour thickness. The LifeMath.net tool was found to appropriately consider tumour thickness, ulceration, age, sex, site and tumour subtype in predicting survival. LIMITATIONS: The authors did not have access to the base data used to compile various prediction tools. CONCLUSION: The LifeMath.net prediction tool is the most reliable for clinicians in counselling patients with newly diagnosed primary cutaneous melanoma regarding their survival prospects.

11.  July 2023           Dixon, A. J., et al. "Improved methodology in determining melanoma mortality and selecting patients for immunotherapy." J Eur Acad Dermatol Venereol 37(7): e843–e845.

12.  June 2022          Dixon, A.J., et al. "Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable." The British journal of dermatology 187(6): 997–998.

13.  May 2022           Steinman, H. K. and Dixon, A. J. and Zachary, C . "Reply to "Correlation of Basal Cell Carcinoma Subtype With Histologically Confirmed Subclinical Extension During Mohs Micrographic Surgery: A Prospective Multi-Center Study"." Journal of the American Academy of Dermatology 87(5): e147–e148.

14.  May 2021           Steinman HK, Dixon A.J., Zachary CB. Commentary on "Superficial Basal Cell Cancers Demonstrate Higher Rates of Mixed Histology on High-Risk Anatomical Sites". Dermatol Surg 20211 47(5): 708–709.

15.  April 2021          Nirenberg A, Steinman H, Dixon A.J., Keratoacanthoma: Update on the Debate. Am J Dermatopathol 2021;43:305-3072

ABSTRACT: Keratoacanthoma (KA) is a cutaneous tumor with a biphasic pattern of growth. A rapidly growing phase is usually followed by involution. KA occurs on sun-damaged skin. There are many listed causative associations, which include some therapeutic agents. Debate continues as to whether KA is a variant of squamous carcinoma (SCC) or a separate entity. Reporting of KA versus SCC is markedly inconsistent. Reasons for inconsistency include overlapping microscopic criteria, variants of KA with more aggressive features, and possibly medicolegal concerns. Genetic studies have shown some differences between the 2 entities. Activation of apoptotic pathways has been demonstrated in KA. Genetic studies have shown a possible role of human polyomavirus 6 in the pathogenesis of at least some KAs. Given that some cases of KA have components that behave as conventional SCCs, KA can be considered as a low-grade variant of SCC with some genetic differences.

16.  July 2020            Nirenberg A, Steinman H, Dixon A. J., et al. Merkel cell carcinoma update: the case for two tumours. J Eur Acad Dermatol Venereol 20193

Merkel cell carcinoma (MCC) is an aggressive tumour with neuroendocrine differentiation. Clinically significant differences within the entity we know as MCC are apparent. This review aims to evaluate the evidence for differences in tumours within Merkel cell carcinoma and to stratify these. A literature search of research pertaining to various characteristics MCC was undertaken from 1972, when Merkel cell carcinoma was first described, to 2018, using PubMed and similar search engines. A total of 41 papers were analysed, including clinical trials, laboratory-based research and reviews. A proportion of MCC has Merkel cell polyomavirus genome integrated (MCPyV+) while others do not (MCPyV-). Both types have a different mutation burden. MCPyV+ tumours are likely true neuroendocrine carcinomas, with a dermal origin, probably from fibroblasts which have been transformed by integration of the viral genome. MCPyV-tumours are likely derived from either keratinocytes or epidermal stem cells, are probably squamous cell carcinomas with neuroendocrine differentiation, and are related to sun damage. Prognostic factors (apart from tumour stage) include the MCPyV status, with MCPyV+ tumours having a better prognosis. P63 expression confers a worse prognosis in most studies. CD8+ lymphocytes play an important role, providing a possible target for PD1/PD-L1 blockade treatment. The incidence of MCC varies from country to country. Countries such as Australia have a high rate and a far greater proportion of MCPyV- tumours than places such as the United Kingdom. MCC doubtlessly encompasses two tumours. The two tumours have demonstrated differences in prognosis and management. One is a neuroendocrine carcinoma related to MCPyV integration likely derived from fibroblasts, and the other is a UV-related squamous cell carcinoma with neuroendocrine differentiation, presumptively derived from either keratinocytes or epidermal stem cells. We propose naming the former Merkel type sarcoma and the latter squamous cell carcinoma, Merkel type.

17.  April 2020          Nirenberg A, Steinman H, Dixon A.J., Melanoma Extravascular Migratory Metastasis: An Important Underrecognized Phenomenon. J Eur Acad Dermatol Venereol 20204

18.  June 2019          Dixon A.J., Steinman H, Nirenberg A, et al. Management of invasive melanoma. Aust J Gen Pract 2019;48:368-372.5

19.  June 2019          Dixon A.J., Steinman H, Anderson S, et al. Cutaneous melanoma: latest developments. Aust J Gen Pract 2019;48:349-353.6

BACKGROUND: Several new medications have shown improved survival rates in high-risk patients with melanoma. OBJECTIVE: The aim of this article is to discuss the new medications and outline their roles, the expected benefit from each and the risk of adverse events. We explain the place of sentinel lymph node biopsy (SLNB) and ultrasonography with fine needle aspiration (US-FNA) in assessing and treating patients with melanoma. DISCUSSION: Ipilimumab has limited efficacy and a very concerning complication profile. More than 50% of patients taking ipilimumab have severe or life-threatening adverse events. BRAF inhibitors have greater efficacy and fewer adverse events than ipilimumab. Combining BRAF inhibitors with mitogen-activated protein kinase inhibitors enhances their effect and improves the overall adverse event profile. BRAF inhibitors are only effective when the melanoma has a BRAF gene mutation, something that occurs in only 50% of cases. Programmed cell death protein 1 medications are also more effective and have a much more acceptable adverse event profile than ipilimumab. Both SLNB and US-FNA can detect early node involvement in patients with melanoma, although US-FNA is a safer procedure

20.  Mar 2019           Carley SK, Dixon A.J., Zachary CB, et al. Revised Mohs surgery care guidelines for squamous cell carcinoma in-situ are overdue. Dermatol Online J 2019;25.7

21.  February 2019               Steinman HK, Dixon A.J., Zachary CB. Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma-Reply. JAMA Dermatol 2019.8

22.  July 2018            Steinman HK, Dixon A.J., Zachary CB. Reevaluating Mohs Surgery Appropriate Use Criteria for Primary Superficial Basal Cell Carcinoma. JAMA Dermatol 2018;154:755-756.9

23.  August 2017     Dixon A.J., Steinman H, Anderson S, et al. Authors' response to a reply to: Re: Routine usage of sentinel node biopsy in melanoma management must cease. Br J Dermatol 2017;177:579-580.10

24.  April 2017          Dixon A.J., Steinman H, Anderson S, et al. Routine usage of sentinel node biopsy in melanoma management must cease. Br J Dermatol 2016;175:1340-1341.11

25.  June 2016          Dixon ZD, A; Anderson S, Dixon, M; Steinman H; Dixon A.J. . Patients more likely to prefer surgery to novel photodynamic therapy. J Clin Exp Dermatol Res 2016;7:2155-9554.12

26.  April 2016          Steinman HK, Clever H, Dixon A.J., The characteristics of Mohs surgery performed by dermatologists who learned the procedure during residency training or through postgraduate courses and observational preceptorships. Proc (Bayl Univ Med Cent) 2016;29:119-23.13

Little is known about the practice characteristics of Mohs surgery performed by physicians who learned the procedure during their dermatology residency training or through postresidency courses and observational preceptorships. All published reports have investigated Mohs surgeons trained in postresidency fellowships. This report presents the results of a multicenter prospective cohort study evaluating 1834 consecutive Mohs surgery cases performed during the same 6-month period by 9 Mohs surgeons who learned the technique in residency or in postresidency courses and observational preceptorships. One major complication was reported, a hematoma requiring outpatient drainage in an emergency room. There were 54 (2.9%) short-term complications, including 20 (1.1%) infections, 17 (0.9%) wound dehiscences, 9 (0.5%) cases of skin flap necrosis, and 8 (0.4%) hematomas or postoperative bleeding episodes. These complication rates and the data evaluating tumor type, anatomic location, primary vs. recurrent tumor status, tumor size, postoperative wound size, number of Mohs surgery stages, and repair type compare favorably to previously published reports.

27.  February 2015 Dixon A.J,, Anderson SJ, Dixon MP, et al. Post procedural pain with photodynamic therapy is more severe than skin surgery. J Plast Reconstr Aesthet Surg 2015;68:28-32.14

OBJECTIVE: To compare prospective data on pain experienced by patients undergoing large facial skin cancer surgery with pain experienced with novel face photodynamic therapy (PDT). DESIGN: A comparison of pain data sets from two prospective trials in the same centre. SETTING: Referral skin cancer centre in Australia. PROTOCOL: 34 PDT patients had two aminolevulinate treatments to the face two weeks apart. 68 Surgery patients, matched 2:1 for gender and age, had large skin cancer excisional surgery to the face and closure with flap, graft or wedge reconstruction. MAIN OUTCOME MEASURE(S): Severity of pain during and following procedure. RESULTS: The only patients describing their experience as the worst pain of their life were 4 PDT patients (12%). The median and mean pain scores for PDT patients were significantly higher than for extensive facial large face surgery, (p<0.001). Further analyses comparing PDT to patients having all skin cancer surgery on the face (N=170) matched for gender and age demonstrated more pain experienced with PDT. PDT is significantly more likely to result in pain requiring strong analgesia or pain beyond strong analgesics than skin cancer surgery including large facial operations. DISCUSSION AND CONCLUSIONS: Clinicians should consider explaining the relative likelihood of more severe pain whenever PDT is considered over surgery. The pain experienced with this PDT product may not reflect the pain experienced with other PDT products

28.  November 2014             Dixon A.J., Anderson S, Steinman HK. How to treat actinic keratoses. Aust Rural Doctor 2014;11:11-14.15

29.  October 2014   Dixon A.J., Nirenberg A, Anderson S, et al. Sentinel lymph node biopsy--reply. Aust Fam Physician 2014;43:665-6.16

30.  July 2014            Dixon A.J., Anderson S, Steinman H, et al. Sentinel lymph node biopsy now has a limited role in melanoma management. Aust Fam Physician 2014;43:479-80.17

31.  April 2014          Dixon A.J., Anderson SJ, Mazzurco JD, et al. Novel photodynamic therapy does not prevent new skin cancers--randomized controlled trial. Dermatol Surg 2014;40:412-9.18

32.  January 2014    Anderson SJ, Steinman HK, Mazzurco JD, Dixon A. J., et al. Prolonged adverse events following photodynamic therapy: regulatory implications. J Drugs Dermatol 2014;13:62-6.19

OBJECTIVE: To determine whether field photodynamic therapy (PDT) of actinic keratoses (AKs) using a novel preparation of 5-aminolevulonic acid (ALA) would result in fewer subsequent invasive skin cancers developing on the face. DESIGN: A prospective multi-center randomized controlled trial. The protocol was approved by the Bond University Human Research Ethics Committee in accord with the TGA's Clinical Trial Notification Scheme. The trial was registered (12609000025235) on the Australian New Zealand Clinical Trials Registry. SETTING: Six centers in four states in Australia. PROTOCOL: Two treatments of ALA PDT, 2 weeks apart for each patient. Controls were observed. Patients were followed up with biopsies of any suspicious lesions every 6 months for 2 years. MAIN OUTCOME MEASURE(S): Development of new skin cancers. RESULTS: The trial was suspended after 3 months and closed after 6 months after ethics committee approval was withdrawn on the basis of a breakdown in trial governance. Over the following 2 years, some investigators noted and formally reported the continued occurrence of serious adverse events in excess of those described with other approved cutaneous PDT treatments. USA dermatologists with experience managing AKs with FDA approved ALA products subsequently confirmed prolonged and severe adverse events in 6 of the former trial intervention patients. DISCUSSION AND CONCLUSIONS: Adverse effects experienced by patients using the investigational ALA PDT appeared more severe than those experienced when an FDA-approved ALA product is used. We believe the former should be further evaluated for safety. It is of concern that this ALA product and lamp could be promoted and used widely in Australia following these reports of significant adverse events and continued lack of TGA approval

33.  January 2013    Dixon A.J., Is sentinel node biopsy in melanoma a test or a treatment? BMJ 2013;346:f677.20

34.  January 2010    Rosengren H, Dixon A.J., Antibacterial prophylaxis in dermatologic surgery: an evidence-based review. Am J Clin Dermatol 2010;11:35-44.21

35.  December 2009             Connelly T, Mones J, Dixon A.J., Ulcerated malignant spindle-cell neoplasm of the finger: malignant peripheral nerve sheath tumor or desmoplastic malignant melanoma? Dermatol Surg 2009;35:2013-8.22

36.  July 2009           Dixon A.J., Dixon MP, Dixon JB. Prospective study of skin surgery in patients with and without known diabetes. Dermatol Surg 2009;35:1035-40.23

37.  July 2009            Dixon A.J., Rosengren H, Connelly T, et al. Education in skin cancer management--assessing knowledge and safety. Aust Fam Physician 2009;38:557-60.24

38.  February 2009 Dixon A.J., Dixon MP, Dixon JB, et al. Prospective study of skin surgery in smokers vs. nonsmokers. Br J Dermatol 2009;160:365-7.25

39.  February 2009 Connelly T, Dixon AJ., Delineating curettage as an adjunct to excision of Basal cell carcinoma: results in 334 cases. Plast Reconstr Surg 2009;123:59e-60e.26

40.  January 2009    Dixon A.J., Dixon MP, Dixon JB. Skin surgery to the ear risks increased bleeding complications--a prospective study. J Plast Reconstr Aesthet Surg 2009;62:123-5.27

41.  September 2008            Dixon A.J., Dixon MP, Dixon JB, et al. Prospective study of skin surgery in smokers vs. nonsmokers. Br J Dermatol 2008.28

42.  May 2008           Dixon A.J., Sentinel lymph node biopsy: Let's get back to basics in managing melanoma. BMJ 2008;336:1033.29

43.  April 2008          Dixon A.J., Dixon MP, Dixon JB. Skin surgery to the ear risks increased bleeding complications - a prospective study. J Plast Reconstr Aesthet Surg 2008.30

44.  November 2007             Dixon A.J., Dixon MP, Dixon JB. Bleeding complications in skin cancer surgery are associated with warfarin but not aspirin therapy. Br J Surg 2007;94:1356-60.31

45.  September 2007            Dixon A.J., Dixon MP, Dixon JB. Prospective study of long-term patient perceptions of their skin cancer surgery. J Am Acad Dermatol 2007;57:445-53.32

46.  August 2007     Dixon A.J., Check Program. Aust Fam Physician 2007;36:583; discussion 583-4.33

47.  July 2007            Dixon A.J., Melanoma management in 2007. Aust Fam Physician 2007;36:488-9.34

48.  June 2007          Dixon A.J., Managing bleeding complications in skin surgery. Aust Fam Physician 2007;36:435-6.35

49.  May 2007           Dixon A.J., Treating actinic keratoses with imiquimod. Aust Fam Physician 2007;36:341-2.36

50.  April 2007          Dixon A.J., Arc welding and the risk of cancer. Aust Fam Physician 2007;36:255-6.37

51.  March 2007       Dixon A.J., Rare skin cancers in general practice. Aust Fam Physician 2007;36:141-3.38

52.  February 2007               Dixon A.J., High risk squamous cell carcinoma. Aust Fam Physician 2007;36:49-50.39

53.  January 2007    Connelly T, Dixon A.J., Surgical pearl: Use of digital Vernier calipers for measurement of lesional and excisional dimensions. J Am Acad Dermatol 2007;56:146.40

54.  December 2006             Dixon A.J., Micronodular basal cell carcinomas. Aust Fam Physician 2006;35:965-6.41

55.  November 2006             Wilkinson D, Bourne P, Dixon A.J., et al. Skin cancer medicine in primary care: towards an agenda for quality health outcomes. Med J Aust 2006;184:11-2.42

56.  November 2006             Dixon A.J., Melanoma with cutaneous melanoma secondaries. Aust Fam Physician 2006;35:871-2.43

57.  October 2006   Dixon A.J., Managing skin cancer below the knee. Aust Fam Physician 2006;35:785-6.44

58.  September 2006            Dixon A.J., Skin cancer in patients with multiple health problems. Aust Fam Physician 2006;35:717-8.45

59.  August 2006     Dixon A.J., Dixon MP, Dixon JB. Randomized clinical trial of the effect of applying ointment to surgical wounds before occlusive dressing. Br J Surg 2006;93:937-43.46

60.  August 2006     Dixon A.J., Dysplastic melanocytic naevus syndrome. Aust Fam Physician 2006;35:601-2.47

61.  July 2006            Dixon A.J., Dixon JB, Dixon MP. Reducing Opposed Multilobed Flaps Results in Fewer Complications Than Traditional Repair Techniques When Closing Medium-Sized Defects on the Leg after Excision of Skin Tumor. Dermatol Surg 2006;32:935-42.48

62.  July 2006            Dixon A.J., One lump or two? A case study of infiltrating BCC on the nose. Aust Fam Physician 2006;35:505-6.49

63.  June 2006          Dixon A,J., Dixon MP, Askew DA, et al. Prospective study of wound infections in dermatologic surgery in the absence of prophylactic antibiotics. Dermatol Surg 2006;32:819-27.50

64.  April 2006          Wilkinson D, Askew DA, Dixon A.J., Skin cancer clinics in Australia: workload profile and performance indicators from an analysis of billing data. Med J Aust 2006;184:162-4.51

65.  January 2006    Dixon A.J., The Multicenter Lymphadenectomy Trial Spells a Halt to Sentinel Node Biopsy. CML Dermatology 2006;11:1-5.52

66.  August 2005     Dixon A.J., Hall RS. Managing skin cancer--23 golden rules. Aust Fam Physician 2005;34:669-71.53

67.  Feb 2005            Dixon A.J., Multiple superficial basal cell carcinomata--topical imiquimod versus curette and cryotherapy. Aust Fam Physician 2005;34:49-52.54

68.  November 2004         Dixon A.J., Dixon MP. Reducing opposed multilobed flap repair, a new technique for managing medium-sized low-leg defects following skin cancer surgery. Dermatol Surg 2004;30:1406-11.55

69.  March 2004       Dixon A.J., Dixon BF. Ultraviolet radiation from welding and possible risk of skin and ocular malignancy. Med J Aust 2004;181:155-7.56